Research
An ulcerative colitis taxonomy defined by individual patient-reported response trajectories
Nature · By Stefan Schreiber ·
The Brief
- An analysis of patient-reported response trajectories to vedolizumab in ulcerative colitis defines disease endotypes.
- The study identifies vascular inflammation as a potential resistance mechanism to vedolizumab.
- The work was published online in Nature Medicine on 9 November 2026 (doi:10.1038/s41591-026-04741-8).
Why it matters
Grouping ulcerative colitis patients by their individual response trajectories could help explain why some patients do not respond to vedolizumab and point to possible targets for treatment resistance.
Who’s affected
- clinicians and researchers in ulcerative colitis and inflammatory bowel disease
- #ulcerative colitis
- #vedolizumab
- #inflammatory bowel disease
- #patient-reported outcomes
- #endotypes
- #vascular inflammation
Nature Medicine, Published online: 09 November 2026; doi:10.1038/s41591-026-04741-8 An analysis of patient-reported trajectories of response to vedolizumab in ulcerative colitis defines disease endotypes and identifies vascular inflammation as a potential resistance mechanism.
Timeline
Study published online in Nature Medicine
nature.com
An ulcerative colitis taxonomy defined by individual patient-reported response trajectories